Background Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested
S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer. Methods …

Background Phase I/II clinical trials of S-1 plus cisplatin for advanced gastric cancer have
yielded good responses and the treatment was well tolerated. In this S-1 Plus cisplatin versus S…

Background Gastrectomy with D2 lymphadenectomy is the standard treatment for curable
gastric cancer in eastern Asia. Whether the addition of para-aortic nodal dissection (PAND) to …

Purpose Radical gastrectomy with regional lymphadenectomy is the only curative treatment
option for gastric cancer. The extent of lymphadenectomy, however, is controversial. The two …

The pharmacological profile and the acute and chronic aquaretic effects of OPC-41061, a
novel nonpeptide human arginine vasopressin (AVP) V 2 -receptor antagonist, were …

Diagnostic and treatment strategies for gastrointestinal stromal tumors (GISTs) have evolved
greatly since the introduction of molecularly targeted therapies. Although several clinical …

OPC-31260, a benzazepine derivative, has been studied for its ability to antagonize the
binding of arginine vasopressin (AVP) to receptors in rat liver (V 1) and kidney (V 2) plasma …

PURPOSE: Previous reports have suggested that mucinous colorectal adenocarcinomas
are more advanced at diagnosis and have a poorer prognosis than nonmucinous colorectal …

Background and Objectives Free cancer cells in the abdominal cavity exfoliated from a tumor
are considered to be responsible for peritoneal dissemination, the most frequent pattern of …

An orally effective, nonpeptide, vasopressin V1 receptor antagonist, OPC-21268, has been
identified. This compound selectively antagonized binding to the V1 subtype of the …